Đorđe Đukanović

Đorđe Đukanović

Auto-generated profile, based on publicly available information

Đorđe Đukanović

Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
Zorislava BajicZorislava Bajic
Zorislava Bajic
Tanja SobotTanja Sobot
Tanja Sobot
SUSnezana Uletilovic
Snezana Uletilovic
NMNebojša Mandić-Kovačević
Nebojša Mandić-Kovačević
TCTanja Cvjetkovic
Tanja Cvjetkovic
RŠRanko Škrbić
Ranko Škrbić
Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular disease, especially myocardial injury. Due to their hypoglycemic effects, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are efficiently used for T2DM management. GLP-1RAs also have anti-inflammatory and antioxidative effects and can improve cardiac function. The aim of this study was to investigate the cardioprotective effects of liraglutide, a GLP-1RA, on isoprenaline-induced myocardial injury in rats. The study included four groups of animals. They were pretreated with saline for 10 days + saline on days 9 and 10 (control), saline for 10 days + isoprenaline on days 9 and 10 (isoprenaline group), liraglutide for 10 days + saline on days 9 and 10 (liraglutide group), and liraglutide for 10 days, and on days 9 and 10 isoprenaline was administered. This study evaluated ECG, myocardial injury markers, oxidative stress markers, and pathohistological changes. The results showed that liraglutide mitigated the isoprenaline-induced cardiac dysfunction recorded by ECG. Liraglutide reduced serum markers of myocardial injury such as high-sensitive troponin I, aspartate aminotransferase, alanine aminotransferase, reduced thiobarbituric acid reactive substances, increased catalase and superoxide dismutase activity, increased reduced glutathione level, and improved lipid profile. Liraglutide induced antioxidative protection and alleviated isoprenaline-induced myocardial injury.

1 March 2024 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
MBMilica Gajic Bojic
Milica Gajic Bojic
MTMarco Treven
Marco Treven
KPKamal P. Pandey
Kamal P. Pandey
VTV.V.N. Phani Babu Tiruveedhula
V.V.N. Phani Babu Tiruveedhula
ASAnja Santrač
Anja Santrač
MSMiroslav M. Savić
Miroslav M. Savić
Hypotensive influences of benzodiazepines and other GABAA receptor ligands, recognized in clinical practice, seem to stem from the existence of “vascular” GABAA receptors in peripheral blood vessels, besides any mechanisms in the central and peripheral nervous systems. We aimed to further elucidate the vasodilatatory effects of ligands acting through GABAA receptors. Using immunohistochemistry, the rat aortic smooth muscle layer was found to express GABAA γ2 and α1-5 subunit proteins. To confirm the role of “vascular” GABAA receptors, we investigated the vascular effects of standard benzodiazepines, midazolam, and flumazenil, as well as the novel compound MP-III-058. Using two-electrode voltage clamp electrophysiology and radioligand binding assays, MP-III-058 was found to have modest binding but substantial functional selectivity for α5β3γ2 over other α xβ3γ2 GABAA receptors. Tissue bath assays revealed comparable vasodilatory effects of MP-III-058 and midazolam, both of which at 100 µmol/L concentrations had efficacy similar to prazosin. Flumazenil exhibited weak vasoactivity per se, but significantly prevented the relaxant effects of midazolam and MP-III-058. These studies indicate the existence of functional GABAA receptors in the rat aorta, where ligands exert vasodilatory effects by positive modulation of the benzodiazepine binding site, suggesting the potential for further quest for leads with optimized pharmacokinetic properties as prospective adjuvant vasodilators.

1 January 2026 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
SMSonja T Marinković
Sonja T Marinković
Tanja SobotTanja Sobot
Tanja Sobot
ŽMŽana M Maksimović
Žana M Maksimović
ÐÐÐorđe Ðukanović
Ðorđe Ðukanović
SUSnezana Uletilovic
Snezana Uletilovic
Miloš P StojiljkovićMiloš P Stojiljković
Miloš P Stojiljković
Acetylcholinesterase (AChE) inhibitors constitute a large and chemically diverse group of compounds that inhibit the enzyme AChE. Some of these compounds that are used to treat Alzheimer’s disease have been reported to have favourable cardiovascular effects, i.e., a 35% reduction of the risk for cardiovascular disease. There has been a growing interest in AchE inhibitors as a potential therapeutic approach for cardiovascular diseases, especially heart failure (HF), since they correct the autonomic imbalance, a key component in the development of heart failure. In the present study, HF was induced in male Wistar albino rats using an isoprenaline model (85 mg/kg/day s.c. for 2 days, followed by 3 weeks of HF development) of heart failure with preserved ejection fraction. Afterwards, rats were treated with pyridostigmine (20 mg/kg/day in tap water for 14 days), while the controls received no treatment. Electrocardiographic and echosonographic measurements were obtained, and samples were taken for antioxidative status measurement and histopathological analysis. Administration of pyridostigmine resulted in preservation of cardiac contractile function (↑ EF), coupled with a decrease in chamber wall thinning (↑ PWDd, ↑ PWDs) and dilatation progression (↓ LVIDd, ↓ LVIDs). Additionally, histopathological findings showed significantly reduced tissue damage score and attenuation of cardiac fibrosis development, indicating the cardioprotective potential of pyridostigmine when used as treatment for the early stages of heart failure; however, further investigations are needed to fully investigate the interplay between the several proposed mechanisms through which AChE inhibitors express their protective effects.

27 January 2025 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
ŽMŽana M Maksimović
Žana M Maksimović
SMSonja T Marinković
Sonja T Marinković
ĐĐĐorđe Đukanović
Đorđe Đukanović
NMNebojša Mandić-Kovačević
Nebojša Mandić-Kovačević
SUSnezana Uletilovic
Snezana Uletilovic
Miloš P StojiljkovićMiloš P Stojiljković
Miloš P Stojiljković
The aim of this study was to determine the antidotal potential of the chlorinated oxime K870 compared to obidoxime, as a monotherapy and in combination with atropine, in paraoxon (POX)-poisoned rats. The treatment doses of oximes were chosen as 20% of their LD50 values. The protective ratio (PR) of oxime K870 with atropine was significantly higher than that of obidoxime with atropine (68.8 and 125.0, respectively). In the biochemical part of the experiment POX subcutaneously (s.c.) (0.75% LD50) was administered and followed by oxime K870 or obidoxime i.m. 1 min later. Acetylcholinesterase (AChE) activity was determined spectrophotometrically in cerebrum, cerebellum, brainstem, diaphragm, and erythrocytes. Carboxylesterase activity was determined in plasma and liver. Both oximes successfully reactivated AChE in brain (cerebrum, cerebellum, and brainstem), diaphragm and erythrocytes, but the oxime K870 performed better than obidoxime. Both oximes reactivated carboxylesterase, obidoxime better in plasma and oxime K870 better in liver. In conclusion, the oxime K870, when co-administered with atropine, is a more effective antidote than the obidoxime-atropine combination in POX-poisoned rats.

1 January 2024 in SCRIPTA MEDICA
Verified
Journal Article
Open access
PDF file
ZMZoran Matković
Zoran Matković
UMUglješa Maličević Uglješa Maličević
Uglješa Maličević Uglješa Maličević
MBMilica Gajic Bojic
Milica Gajic Bojic
AKAleksandra Krivokuća
Aleksandra Krivokuća
ĐĐĐorđe Đukanović
Đorđe Đukanović
ZMZoran Matkovic
Zoran Matkovic
Acute mesenteric ischaemia (AMI) is a serious disease with mortality between 50 and 80 %. Oxidative stress plays a major role in the pathophysiology of AMI. AMI should be considered for any acute abdominal pain that requires analgesia with morphine and for which no other obvious aetiology is found. CT is the main diagnostic procedure to confirm the diagnosis of AMI. There is no specific diagnostic biomarker for AMI that can be used in routine practice. AMI is an urgent diagnostic and therapeutic situation. Treatment of AMI includes a protocol combining digestive rest, curative anticoagulant, antiplatelet, antibiotic therapy, arterial revascularisation to salvage viable bowel and resection of necrotic digestive segments. The strategy of revascularisation depends on the mechanism of arterial occlusion, the morphological appearance of the lesions and the indications for exploratory laparotomy. Endovascular and open surgical techniques can be combined and complemented. Open surgical revascularisation is indicated in case of failure or impossibility of endovascular revascularisation and in case of need for laparotomy. Early diagnosis and timely surgical intervention are the cornerstones of modern treatment to reduce the high mortality of AMI. The emergence of endovascular approaches and modern imaging techniques is developing and providing new treatment options. A multidisciplinary approach based on early diagnosis and treatment is necessary.